Disease area studied	Abbreviated title	Phase	Study ID	Registry database	Study results	Publication (if available)
Ankylosing Spondylitis	A Multicenter Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis	Phase 2	AS0008 Completed	NCT02963506 2016-001102-42	LINK	van der Heijde D., Arthritis Rheumatol 2019; 71(Suppl 10), abs 0937
Ankylosing Spondylitis	A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis	Phase 2	AS0009 Ongoing	NCT03355573 2017-001002-15
Nonradiographic Axial Spondyloarthritis	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis	Phase 3	AS0010 Ongoing	NCT03928704 2017-003064-13
Ankylosing Spondylitis	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis	Phase 3	AS0011 Ongoing	NCT03928743 2017-003065-95
Ankylosing Spondylitis	Study to evaluate the efficacy and safety of Bimekizumab compared to Certolizumab Pegol in the treatment of subjects with active ankylosing spondylitis (AS)	Phase 2	AS0013 Completed	NCT03215277 2017-000957-37
Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis	A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis (BE MOVING)	Phase 3	AS0014 Ongoing	NCT04436640 2019-004163-47
Chronic Plaque Psoriasis	A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)	Phase 3	DV0002 Ongoing	NCT03766685
Psoriatic Arthritis	The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after training in self-injection technique using the bimekizumab safety syringe (SS) or the bimekizumab auto-injector (AI).	Phase 3	DV0004 Ongoing	NCT04109976
Chronic Plaque Psoriasis	A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)	Phase 3	DV0006 Ongoing	2016-003427-30
Hidradenitis Suppurativa	A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.	Phase 2	HS0001 Completed	NCT03248531 2017-000892-10	LINK
Hidradenitis Suppurativa	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD I)	Phase 3	HS0003 Ongoing	NCT04242446 2019-002550-23
Hidradenitis Suppurativa	A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD II)	Phase 3	HS0004 Ongoing	NCT04242498 2019-002551-42
Psoriatic Arthritis	A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis	Phase 2	PA0008 Completed	NCT02969525 2016-001103-23		Ritchlin C.T. et al. The Lancet 2020; 395(10222):427–40
Psoriatic Arthritis	A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis	Phase 2	PA0009 Ongoing	NCT03347110 2017-001003-74
Psoriatic Arthritis	A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis	Phase 3	PA0010 Ongoing	NCT03895203 2017-002322-20
Psoriatic Arthritis	A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis	Phase 3	PA0011 Ongoing	NCT03896581 2017-002804-29
Psoriatic Arthritis	A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis	Phase 3	PA0012 Ongoing	NCT04009499 2018-004725-86
Chronic Plaque Psoriasis	A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 3	PS0008 Completed	NCT03412747 2016-003392-22
Chronic Plaque Psoriasis	A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 3	PS0009 Completed	NCT03370133 2016-003425-42
Chronic Plaque Psoriasis	Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients with Chronic Plaque Psoriasis	Phase 2	PS0010 Completed	NCT02905006 2016-001891-31	LINK	Papp K.A., et al. J Am Acad Dermatol 2018; 79(2):277–286
Chronic Plaque Psoriasis	A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis	Phase 2	PS0011 Completed	NCT03010527 2016-001892-57		Blauvelt, A. et al. Ann Rheum Dis 2019; 78 (Suppl. 2), s. 1834
Chronic Plaque Psoriasis	A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 3	PS0013 Completed	NCT03410992 2016-003426-16
Chronic Plaque Psoriasis	A Study to Assess the Safety, Tolerability and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 3	PS0014 Ongoing	NCT03598790 2016-003427-30
Chronic Plaque Psoriasis	A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 3	PS0015 Ongoing	NCT03536884 2017-003784-35
Chronic Plaque Psoriasis	A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis	Phase 2	PS0016 Completed	NCT03025542 2016-002368-15
Chronic Plaque Psoriasis	A Multicenter, 48-week, Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis.	Phase 2	PS0018 Completed	NCT03230292 2016-002934-57
Rheumatoid arthritis	Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis	Phase 2	RA0123 Completed	NCT02430909 2014-003307-30	LINK	Glatt et al. Annals of the rheumatic diseases 2019 [ePub]
Ulcerative Colitis	A study to test the effectiveness of bimekizumab as a treatment for ulcerative colitis to look for unwanted side effects and to measure how the drug is distributed, modified and cleared from the body.	Phase 2	UC0011 Terminated	2016-000420-26	LINK

Our Company

Disease Areas

Our Science

UCB Worldwide

Our Products

Newsroom

Patients

Investors

HCP

Clinical Studies

Advantage Hers

bimekizumab - UCB4940